A phase ii trial of combined chemotherapy and surgery in stage iiia non-small cell lung cancer

Autor: Rino Vitali, Paolo Latini, Tommaso Todisco, Paolo Fiaschini, S. Darwish, Checcaglini F, Maurizio Tonat, Michele Giansanti, Ernesto Maranzano, Vincenzo Minotti, Lucio Crinò, Riccardo Rossetti, Ugo Mercati
Rok vydání: 1995
Předmět:
Zdroj: Lung Cancer. 12:S71-S78
ISSN: 0169-5002
DOI: 10.1016/0169-5002(95)00422-w
Popis: A poor prognosis for patients with Stage IIIA clinical N2 treated by surgery alone has led clinical researchers to find a new treatment modality to improve the curative potential of surgery. Many Phas II trials have been carried out with induction chemo- or chemo-radiotherapy prior to surgery. From June 1988 to July 1991, 46 patients with non-small cell lung cancer (NSCLC) Stage IIIA clinical N2 entered a Phase II induction-chemotherapy trial. Patients received 2-3 cycles of high-dose cisplatin and etoposide. Forty-five were evaluable for response; the response rate was 82% (37/45: 3 CR, 34 PR). Toxicity was primarily hematologic. Surgical resection was performed in 35 patients; radical resection was possible in 28 patients (62%); three patients were incompletely resected and two patients were only explored. Three deaths were surgery-related. Median survival was 24.5 months with a 2-year survival of 53%. Cisplatin with etoposide is an active and safe induction chemotherapy regimen for NSCLC Stage IIIA N2 with a high response rate. The median survival seems to be prolonged and therefore, randomized trials are needed to compare this approach with other treatment modalities.
Databáze: OpenAIRE
Externí odkaz: